Nucleated red blood cell: a feasible quality parameter of cord blood units

Kondo, Andrea Tiemi; Alvarez, Kelen; Cipolletta, Andrea Neri Folchini; Sakashita, Araci Massami; Kutner, José Mauro

doi:10.1016/j.htct.2023.01.009

Cited by 1 publication

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Critically, donor CB characteristics are a determinant for the efficacy of CAR NK cells in the treatment of B-cell tumors, with optimal CBUs being defined as those that were cryopreserved within 24 h of collection (which is a shorter time than the 48 h metric commonly used in the banking industry) and that had less than 8 Â 10 7 total nucleated red blood cells [66 && ]. Interestingly, recent reports suggest that nRBC levels in CBU can provide a predictive measure for clinical utility in transplant and be useful as a banking strategy [67,68]. As such, nRBC content should be further examined in relation to CBU utility critical for different clinical uses.…”

Section: Cord Blood Derived Chimeric Antigen Receptor T/ Chimeric Ant...mentioning

confidence: 99%

The fulfilled promise and unmet potential of umbilical cord blood

Ropa,

Van’t Hof

2024

Current Opinion in Hematology

View full text Add to dashboard Cite

Purpose of review Here, we review classic and emerging uses of umbilical cord blood and highlight strategies to improve its utility, focusing on selection of the appropriate units and cell types for the intended applications. Recent literature Recent studies have shown advancements in cord blood cell utility in a variety of cellular therapies and have made strides in elucidating manners to select the best units for therapy and target new ways to improve the various cell subpopulations for their respective applications. Summary Umbilical cord blood is a proven source of cells for hematopoietic cell transplantation and research and is an important potential source for additional cellular therapies. However, cord blood utility is limited by low “doses” of potent cells that can be obtained from individual units, a limitation that is specific to cord blood as a donor source. In addition to traditional CD34+ progenitor cells, cord blood lymphocytes are being pursued as therapeutic entities with their own unique properties and characteristics. Thus, selection of ideal units depends on the intended therapeutic entity and target, and identification of differential potency parameters is critical to drive effective banking strategies accommodating successful clinical use of cord blood in broader cell therapy settings.

show abstract

Section: Cord Blood Derived Chimeric Antigen Receptor T/ Chimeric Ant...mentioning

confidence: 99%